67
Participants
Start Date
March 1, 2004
Primary Completion Date
November 1, 2005
Study Completion Date
June 1, 2006
Teduglutide (ALX-0600)
0.1 mg/kg injected subcutaneously daily
Asher Kornbluth, MD, PC, New York
Long Island Clinical Research Associates, Great Neck
Rx Trials, Washington D.C.
McGuire DVAMC, Richmond
Wake Research Associates, Raleigh
Pinnacle Trials, Atlanta
Saint Joseph's Health System, Atlanta
Venture Research, North Miami Beach
Clinical Trials Management of Boca Raton, Boca Raton
Clinical Research of West Florida, Clearwater
University of Louisville, Louisville
Cleveland Clinic Foundation, Cleveland
Dean Foundation Research Center, Madison
Northwestern University School of Medicine, Chicago
University of Chicago, Chicago
Lynn Health Science Institute, Oklahoma City
Atilla Ertan, Houston
Rocky Mountain Gastroenterology, Lakewood
University of Utah, Salt Lake City
Advanced Clinical Therapeutics, Tucson
Vancouver General Hospital, Vancouver
Health Sciences Center, Winnipeg
Queen Elizabeth II Health Sciences, Halifax
Life Screening Centres, Toronto
Lead Sponsor
Shire
INDUSTRY